can 503a compound tirzepatide Navigating Uncertainty in Compounding – Current Status for and 503B Compliance Compounded Tirzepatide 2026: Dosage, Cost,

Trying to inject the remaining liquid is dangerous and should not be attempted

This section reflects publicly available FDA information as of June 2026

By transitioning from daily basal insulin injections to just one per week, Awiqli 's convenience ultimately provides the choice for potentially more patients living with diabetes in need of basal insulin to better manage their condition," said Dr

How retatrutide compares to current options A short comparison helps put the mechanism in context

Both are administered as once-weekly injections

The FDA has also flagged BPC-157 as a bulk drug substance that may present significant safety risks when used in compounding, noting limited safety information and concerns like immunogenicity for certain routes of administration and peptide-related impurities